Literature DB >> 19420086

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Linda S Wyatt1, Patricia L Earl, Wei Xiao, Jeffrey L Americo, Catherine A Cotter, Jennifer Vogt, Bernard Moss.   

Abstract

While characterizing modified vaccinia virus recombinants (rMVAs) containing human immunodeficiency virus env and gag-pol genes, we detected nonexpressing mutants by immunostaining individual plaques. In many cases, the numbers of mutants increased during successive passages, indicating strong selection pressure. This phenomenon provided an opportunity to investigate the formation of spontaneous mutations in vaccinia virus, which encodes its own cytoplasmic replication system, and a challenge to reduce the occurrence of mutations for vaccine production. Analysis of virus from individual plaques indicated that loss of expression was due to frameshift mutations, mostly by addition or deletion of a single nucleotide in runs of four to six Gs or Cs, and large deletions that included MVA DNA flanking the recombinant gene. Interruption of the runs of Gs and Cs by silent codon alterations and moving the recombinant gene to a site between essential, highly conserved MVA genes eliminated or reduced frameshifts and viable deletion mutants, respectively. The rapidity at which nonexpressing mutants accumulated depended on the individual env and gag-pol genes and their suppressive effects on virus replication. Both the extracellular and transmembrane domains contributed to the selection of nonexpressing Env mutants. Stability of an unstable Env was improved by swapping external or transmembrane domains with a more stable Env. Most dramatically, removal of the transmembrane and cytoplasmic domains stabilized even the most highly unstable Env. Understanding the causes of instability and taking preemptive actions will facilitate the development of rMVA and other poxviruses as human and veterinary recombinant vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420086      PMCID: PMC2704791          DOI: 10.1128/JVI.00687-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Illegitimate recombination in bacteria and bacteriophage.

Authors:  R A Weisberg; S Adhya
Journal:  Annu Rev Genet       Date:  1977       Impact factor: 16.830

2.  Purification and properties of the deoxyribonucleic acid polymerase induced by vaccinia virus.

Authors:  M D Challberg; P T Englund
Journal:  J Biol Chem       Date:  1979-08-25       Impact factor: 5.157

3.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Authors:  H Stickl; V Hochstein-Mintzel; A Mayr; H C Huber; H Schäfer; A Holzner
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

4.  Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

Authors:  K J Stittelaar; T Kuiken; R L de Swart; G van Amerongen; H W Vos; H G Niesters; P van Schalkwijk; T van der Kwast; L S Wyatt; B Moss; A D Osterhaus
Journal:  Vaccine       Date:  2001-06-14       Impact factor: 3.641

5.  Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development.

Authors:  Dennis L Ellenberger; Bin Li; L Davis Lupo; S Michele Owen; John Nkengasong; Madeleine Sassan Kadio-Morokro; James Smith; Harriet Robinson; Marta Ackers; Alan Greenberg; Thomas Folks; Salvatore Butera
Journal:  Virology       Date:  2002-10-10       Impact factor: 3.616

6.  Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

Authors:  K J Stittelaar; L S Wyatt; R L de Swart; H W Vos; J Groen; G van Amerongen; R S van Binnendijk; S Rozenblatt; B Moss; A D Osterhaus
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Studies on vaccinia virus-directed deoxyribonucleic acid polymerase.

Authors:  R V Citarella; R Muller; A Schlabach; A Weissbach
Journal:  J Virol       Date:  1972-10       Impact factor: 5.103

8.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

9.  Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.

Authors:  James M Smith; Rama Rao Amara; Harold M McClure; Milloni Patel; Sunita Sharma; Hong Yi; Lakshmi Chennareddi; James G Herndon; Salvatore T Butera; Walid Heneine; Dennis L Ellenberger; Bharat Parekh; Patricia L Earl; Linda S Wyatt; Bernard Moss; Harriet L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2004-06       Impact factor: 2.205

Review 10.  The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

Authors:  Carmen E Gómez; José L Nájera; Magdalena Krupa; Mariano Esteban
Journal:  Curr Gene Ther       Date:  2008-04       Impact factor: 4.391

View more
  42 in total

1.  Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.

Authors:  Edwin R Manuel; Zhongde Wang; Zhongqi Li; Corinna La Rosa; Wendi Zhou; Don J Diamond
Journal:  Virology       Date:  2010-05-14       Impact factor: 3.616

2.  Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus.

Authors:  Tatiana G Senkevich; Erik K Zhivkoplias; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 3.  Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

Authors:  Lynette Siv Chea; Rama Rao Amara
Journal:  Expert Rev Vaccines       Date:  2017-09-04       Impact factor: 5.217

Review 4.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

5.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.

Authors:  Genevieve G A Fouda; Joshua D Amos; Andrew B Wilks; Justin Pollara; Caroline A Ray; Anjali Chand; Erika L Kunz; Brooke E Liebl; Kaylan Whitaker; Angela Carville; Shannon Smith; Lisa Colvin; David J Pickup; Herman F Staats; Glenn Overman; Krissey Eutsey-Lloyd; Robert Parks; Haiyan Chen; Celia Labranche; Susan Barnett; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Hua-Xin Liao; Norman L Letvin; Barton F Haynes; Sallie R Permar
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

7.  Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node.

Authors:  Wolfgang Kastenmüller; Marlene Brandes; Ze Wang; Jasmin Herz; Jackson G Egen; Ronald N Germain
Journal:  Immunity       Date:  2013-01-24       Impact factor: 31.745

8.  A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread.

Authors:  Wolfgang Kastenmüller; Parizad Torabi-Parizi; Naeha Subramanian; Tim Lämmermann; Ronald N Germain
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

9.  Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Authors:  Patricia L Earl; Catherine Cotter; Bernard Moss; Thomas VanCott; Jeffrey Currier; Leigh Anne Eller; Francine McCutchan; Deborah L Birx; Nelson L Michael; Mary A Marovich; Merlin Robb; Josephine H Cox
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.